An observational study in Peripheral Arterial Disease(PAD), sponsored by Wroclaw Medical University. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Wroclaw Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is one of 5 that started in 2025, is one of 3 observational ones, and was the 30th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Argentina and 15 more countries
Ages 18+
MDCECRO LLC · Sites in Poland
Ages 18–80
Balton Sp.zo.o. · Sites in Poland, Spain
Ages 18+
CSL Behring · Sites in Poland, United States, Argentina and 32 more countries
Ages 18+
Grena Biomed Limited · Sites in Poland, Belgium
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 11 · Phase 4 1
First in 2007; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 220 across the 28 interventional studies, 300 across the 3 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 31 have an industry lead sponsor. The 10 most frequent:
Wroclaw Medical University is the lead sponsor of 99 studies on the registry; 29 are open to participants now.
Wroclaw Medical University has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07157475Wroclaw Medical UniversityVascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors | 2026-12-31 |
| NCT07122167MDCECRO LLCPost-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions | 2026-12-31 |
| NCT04349657KANDO ResearchA Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy | 2027-05 |
| NCT07049120Zhejiang Zylox Medical Device Co., Ltd.Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures. Patients who are at least one year post-procedure will be contacted by phone and asked whether any cardiovascular complications occurred during that period, specifically major adverse cardiovascular events (MACE) or major adverse limb events (MALE), and whether they had been taking sodium-glucose co-transporter 2 inhibitors (SGLT2-i, "flozins") during the year following the procedure. The results from the group of pts who, for any reason, received SGLT2-i treatment after the vascular procedure (including those who had initiated treatment before surgery) will be compared to the results from the group of patients who did not receive such treatment, with regard to the occurrence of the aforementioned complications.
Project Objective: To assess the impact of SGLT2 inhibitors (SGLT2-i) on vascular complications in patients undergoing peripheral revascularization.
Specific Objective: To evaluate the incidence of 3-point MACE* (Major Adverse Cardiac Events) and MALE** (Major Adverse Limb Events) following vascular surgical procedures (both open and minimally invasive), performed in patients treated with SGLT2- i vs controls ( non-treated pts).
Observation Period: One year - assessment at 30 days, 3 months, and 1 year post-procedure.
Definitions for:
* MACE = Non-fatal myocardial infarction (MI),Non-fatal stroke involving the central nervous system (CNS), Cardiovascular death
** MALE = Untreated restenosis or deterioration in patency of a previously revascularized vessel , Reintervention in the revascularized segment due to impaired patency, Amputation (either above or below the knee) of the revascularized limb.
Demographic and clinical data will be obtained from the medical records of patients hospitalized in three vascular surgery departments (Wrocław, Poznań, Warsaw), while information regarding MACE , MALE, and the use of SGLT2-i will be collected via telephone interviews with the patients (or their family members, if the patient is deceased).
The number of MACE and MALE incidents during the year following the procedure will be compared between the two groups.
The analyzed cases will involve patients from three major vascular clinics located in Wrocław, Poznań, and Warsaw.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and, for any reason, were treated with SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.
Drug: Treatment with SGLT2 inhibitors (flozins)
Patients aged ≥18 years who have undergone vascular surgery (either open or minimally invasive procedures) and were not exposed to SGLT2 inhibitors ("flozins") during the one-year follow-up period after the procedure.
Drug page: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients received SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as part of their routine clinical care during the 12-month follow-up period after elective or urgent lower limb revascularization procedures. The study does not assign treatment; medication use occurred independently of the study protocol.
MACE (Major Adverse Cardiovascular Events) and MALE (Major Adverse Limb Events)-Number of Participants Experiencing MACEor MALE
MACE is defined as a composite of : Non-fatal myocardial infarction (MI); Non-fatal stroke involving the central nervous system (CNS); or Cardiovascular death MALE is defined as a composite of : Untreated loss or deterioration of patency in a previously revascularized vessel; Repeat intervention in a revascularized segment due to impaired patency, or Amputation (above or below the knee) of the revascularized limb Unit of Measure: Number of participants with at least one event
Time frame: 12 months from the vascular intervention
Non-fatal Myocardial Infarction (MI)
Non-fatal myocardial infarction (MI), Unit of Measure: Number of participants Non-fatal stroke involving the central nervous system (CNS) Cardiovascular death Untreated loss or deterioration of patency in a previously revascularized vessel Repeat intervention in a revascularized segment due to impaired patency Amputation (above or below the knee) of the revascularized limb
Time frame: 12 months from the vascular intervention
Non-fatal Stroke Involving the Central Nervous System (CNS)
Non-fatal Stroke Involving the Central Nervous System (CNS), Unit of Measure: Number of participants
Time frame: 12 months from the vascular intervention
Cardiovascular Death
Cardiovascular Death, Unit of Measure: Number of participants
Time frame: 12 months from the vascular intervention
Loss or Deterioration of Patency in a Previously Revascularized Vessel
Loss or Deterioration of Patency in a Previously Revascularized Vessel, Unit of Measure: Number of participants
Time frame: 12 months from the vascular intervention
Repeat intervention in a revascularized segment due to impaired patency
Repeat intervention in a revascularized segment due to impaired patency; Unit of Measure: Number of participants and number of limbs
Time frame: 12 months from the vascular intervention
Amputation of the revascularized limb
Amputation (above or below the knee) of the revascularized limb; Unit of Measure: Number of participants and number of limbs
Time frame: 12 months from the vascular intervention
Additional secondary endpoint- Surgical site infection (SSI)
Surgical site infection occurring after the index vascular intervention. Unit of Measure: Number of participants
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Significant bleeding
Clinically significant bleeding events as assessed by treating physician (according to established clinical criteria). Unit of Measure: Number of participants
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Kidney injury
Acute kidney injury occurring after vascular intervention, defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Unit of Measure: Number of participants
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Reintervention in the Same Vascular Segment
Readmission and repeat procedure in the same vascular segment due to impaired patency. Unit of Measure: Number of participants and number of limbs
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Foot Necrosis
Development of necrosis in the treated limb within the study period. Unit of Measure: Number of participants and number of limbs
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Minor Amputation
Minor amputation defined as amputation within the foot (below the ankle). Unit of Measure: Number of participants and number of limbs
Time frame: 12 months from vascular intervention
Additional secondary endpoint- Heart Failure Hospitalization
Hospital admission with a primary diagnosis of heart failure. Unit of Measure: Number of participants
Time frame: 12 months from vascular intervention
Plan to share: Yes — only IPD used in the results publication
Supporting information: Study protocol
Time frame: Individual participant data (de-identified) and supporting documents will be available upon reasonable request from qualified researchers, starting 6 months after publication of the primary results and for a period of 5 years.
Access criteria: Anonymized individual participant data (IPD) may be shared upon reasonable request. Access will be considered for qualified researchers with a valid scientific proposal. Requests will be reviewed by the study team, and a data sharing agreement may be required.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wroclaw Medical University